BIM
TBPH icon

Bogle Investment Management’s Theravance Biopharma TBPH Stock Holding History

Bogle Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,550
Closed -$201K – 406
2016
Q3 		$201K Sell
5,550
-109,953
-95% -$3.06M 0.01% 334
2016
Q2 		$2.62M Buy
+115,503
New +$2.49M 0.18% 154

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bogle Investment Management's TBPH Position: Q4 2016 in Review

Bogle Investment Management sold out of Theravance Biopharma (TBPH) in Q4 2016, closing a stake of 5,550 shares — an estimated $201K sold.

Bogle Investment Management first reported a position in TBPH in Q2 2016 and held it in 2 quarters. The position peaked at $2.62M in Q2 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

  • Bogle Investment Management reported no remaining Theravance Biopharma position as of Q4 2016 after selling out during the quarter.
  • Bogle Investment Management sold 5,550 Theravance Biopharma shares in Q4 2016, an estimated $201K.
  • Bogle Investment Management first reported a position in Theravance Biopharma in Q2 2016 and held it in 2 quarters.
  • Bogle Investment Management's Theravance Biopharma position peaked at $2.62M in Q2 2016.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on Bogle Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.